About

Pharmaceutical expertise. Applied through a trusted network.

We orchestrate pharmaceutical development, manufacturing and quality, coordinating certified production partners with the discipline of two decades on the factory floor.

Mission

Inventis was founded to bring decades of European pharmaceutical manufacturing discipline to the GCC and Middle East market. The objective is operator-defined: medicinal products developed, manufactured and released to a quality standard that withstands scrutiny from regulators, partners and patients.

We are not advisors. We are not brokers. We are pharmaceutical operators, coordinating production through a qualified network of GMP-certified manufacturers.

What we do

Pharmaceutical development (galenic, analytical, stability)
Manufacturing coordination across solid, liquid, semi-solid and injectable forms
Quality control and quality assurance
Tech transfer and scale-up
Regulatory and dossier support (CTD, ACTD)

Our model

Inventis operates as an asset-light pharmaceutical company. Development and quality oversight are in-house disciplines; manufacturing is delivered through a curated network of GMP-certified facilities holding ISO 9001, ISO 14001 and ISO 45001 certifications.

This model offers structural advantages: access to multiple production lines without capital expenditure, no single point of failure in the supply chain, and quality oversight that is independent from production, built on the expertise of people who spent two decades building and running pharmaceutical factories in Europe.

CEO, Inventis & Qantaris

Paulo Paiva dos Santos

Founder and former CEO of Generis Farmacêutica, Portugal's leading pharmaceutical company, with thirty years in the pharmaceutical industry, twenty of them built on the factory floor across Europe and emerging markets.

Paulo founded Generis in 2002 to bring high-quality medicines to the Portuguese market. By 2006 the company had acquired and commissioned a manufacturing facility producing over 1.2 billion tablets per year, a €32 million investment. Under his leadership Generis grew to 271 marketed products and approximately €80 million in revenue, becoming Portugal's number-one pharmaceutical brand before its acquisition by Aurobindo Pharma in 2017.

A Harvard Business School and Oxford alumnus, Paulo now leads Inventis and Qantaris from Dubai, applying the same operational discipline to pharmaceutical development, manufacturing coordination and quality oversight through a curated network of GMP-certified facilities serving the Middle East and beyond.

He also serves as President of the Portuguese Business Council, established by Dubai Chambers.

Where we operate

Two offices. One operation.

38.7223° N, 9.1393° W

Lisbon

Portugal

Rua Barata Salgueiro 37

1250-042 Lisbon

European development coordination and regulatory strategy.

25.1865° N, 55.2782° E

Dubai

United Arab Emirates

Bay Square, Building 4, 2nd Floor

Business Bay, P.O. Box 14110

Manufacturing oversight, quality assurance and GCC, Middle East operations.

Industrial heritage

Built on the factory floor. Two decades in pharmaceutical manufacturing.

Inventis carries the operational DNA of three European pharmaceutical manufacturing facilities built, commissioned and operated across Portugal and Spain by Paulo Paiva dos Santos, over three decades. A portfolio of 250+ molecules developed and commercialised. Over 20 of those years spent running production at industrial scale, from granulation to finished product release.

That experience is not advisory background. It is the operating foundation of everything Inventis does today.

Operators, not advisors. Industry, not brokerage.

Meet the leadership

2006

Generis

Inaugurated a €32 million pharmaceutical factory in Portugal, 3,600 m² of production area, CFR 11-compliant and FDA-ready, under the leadership of Paulo Paiva dos Santos.

2008

Generis

Acquisition of a second manufacturing site in Sete Casas, Loures, Portugal. Expanded production capacity into powder sachets, introducing a new dosage form to the portfolio.

2010

Wynnova

Third manufacturing site established in Getafe, Madrid, Spain. Solid oral forms and liquids. Capacity: 24.8 million units per year.

2006 – 2020s

Industrial DNA carried forward

Two decades of pharmaceutical development, manufacturing and regulation across European and emerging markets. 150+ medicines brought to market.

Present

Inventis

Pharmaceutical operation across Europe and the Middle East: galenic development, manufacturing coordination and quality oversight through a curated network of certified facilities, serving the GCC, Middle East and beyond.